This Article Full Text Full Text (PDF) All Versions of this Article: 51/6/1531    most recent HYPERTENSIONAHA.107.105171v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gamboa, A. Articles by Biaggioni, I. Search for Related Content PubMed PubMed Citation Articles by Gamboa, A. Articles by Biaggioni, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Clinical Studies Other etiology Autonomic, reflex, and neurohumoral control of circulation Endothelium/vascular type/nitric oxide

(Hypertension. 2008;51:1531.)
© 2008 American Heart Association, Inc.

Original Articles

Excessive Nitric Oxide Function and Blood Pressure Regulation in Patients With Autonomic Failure

Alfredo Gamboa; Cyndya Shibao; André Diedrich; Sachin Y. Paranjape; Ginnie Farley; Brian Christman; Satish R. Raj; David Robertson; Italo Biaggioni

From the Department of Medicine, Vanderbilt University, Nashville, Tenn.

Correspondence to Italo Biaggioni, 1500 21st Ave South, Suite 3500, Vanderbilt University, Nashville, TN 37212. E-mail italo.biaggioni{at}vanderbilt.edu

Approximately 50% of patients with autonomic failure (AF) suffer from supine hypertension, even those with very low plasma norepinephrine and renin. Because NO is arguably the most potent metabolic modulator of blood pressure, we hypothesized that impaired NO function contributes to supine hypertension in AF. However, we found that AF patients (n=14) were more sensitive to the pressor effects of the NO synthase inhibitor N^G-monomethyl-L-arginine, suggesting increased NO function rather than deficiency; a lower dose of N^G-monomethyl-L-arginine was needed to produce a similar increase in blood pressure in AF patients, as in healthy control subjects in whom AF was induced with the ganglionic blocker trimethaphan (171±37 mg versus 512±81 mg, respectively; P=0.001). Furthermore, potentiation of the actions of endogenous NO with the phosphodiesterase inhibitor sildenafil (25 mg PO) decreased nighttime supine systolic blood pressure from 182±11 to 138±4 mm Hg in 8 AF patients with supine hypertension (P=0.012 compared with placebo). Finally, AF patients tolerated a greater degree of upright tilt during infusion of N^G-monomethyl-L-arginine (56±6° versus 41±4° with placebo; n=7; P=0.014), an improvement in orthostatic tolerance similar to that obtained with equipressor doses of phenylephrine. In conclusion, AF patients do not have NO deficiency contributing to supine hypertension. Instead, they have increased NO function contributing to their orthostatic hypotension. Potentiation of NO could be used in the treatment of supine hypertension, and its inhibition offers a novel approach to improve orthostatic hypotension.

Key Words: NO • orthostatic hypotension • supine hypertension • pure autonomic failure • Shy-Drager syndrome • blood pressure • L-NMMA

This article has been cited by other articles:

				G. D. Fink Sympathetic Activity, Vascular Capacitance, and Long-Term Regulation of Arterial Pressure Hypertension, February 1, 2009; 53(2): 307 - 312. [Full Text] [PDF]